OneMedNet Announces AI Partnership and Claims Strong 2025 Financials, But Liquidity and Scale Risks Persist

What happened

OneMedNet issued a press release touting strong 2025 financial results and advancements in its AI-driven iRWD platform through a partnership with Palantir Foundry. The company emphasizes this enables conversational search on real-time medical data, positioning it to capitalize on growing demand for imaging-centric real-world data. However, the DeepValue report reveals that as of June 2025, OneMedNet had only $0.1 million in cash and $1.6 million in Bitcoin, with a going-concern flag and dependence on external financing likely leading to dilution. Revenue remains sub-scale at $155,000 in Q2 2025, and Nasdaq noncompliance notices create delisting risk, overshadowing the strategic pivot from decommissioned BEAM services. This announcement appears promotional, lacking specific financial details to address the critical liquidity and execution challenges documented in regulatory filings.

Implication

The AI partnership with Palantir could enhance OneMedNet's iRWD offerings, but it fails to immediately resolve the acute cash shortage and going-concern uncertainties highlighted in the report. Without disclosed contract values or revenue impacts, the announcement offers little evidence of iRWD traction needed to shift from a SELL stance, such as consecutive quarters over $1 million in iRWD revenue. Liquidity remains precarious, relying on a $25 million equity facility that may dilute shareholders, and Nasdaq compliance overhangs could trigger a reverse split or delisting. Investors must watch for concrete signs of improved cash flow, secured non-dilutive funding, or multi-year contracts to reassess the risk profile. Until then, the equity is high-risk, and any optimism from this news should be tempered by the company's history of losses and competitive pressures from larger RWD platforms.

Thesis delta

No material shift in the SELL thesis; the announcement lacks specific financial metrics or liquidity solutions to counter the report's concerns about scale and financing reliance. If the Palantir partnership leads to measurable iRWD bookings or strategic validation with upfront payments, it could be a minor positive, but current information is insufficient to alter the high-risk assessment.